| Value | ₹15.58 Cr |
|---|
BSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹28.61
- Market cap
- ₹45.28 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 45.9×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Board Meeting Date
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Mangalam Drugs and Organics Other Announcement
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Other adverse business impact announcements
All →Medplus Health Services Adverse Business Impact
MedPlus Health Services' subsidiary Optival Health Solutions had its drug licence suspended for five days for a Suryapet store. Expected financial impact is about Rs 1.32 lakh.
- Value
- ₹0.01 Cr
- Execution
- 05 days
Oriental Rail Infrastructure Adverse Business Impact
Oriental Rail's subsidiary Oriental Foundry had a fire at its Kutch plant on 28 October 2026. Damage is minimal, operations are unaffected and the loss is insured.
Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr
Hindustan Organic Chemicals Adverse Business Impact
Hindustan Organic Chemicals temporarily shuts down its Kochi Hydrogen plant from 29 October 2026 for pipeline repair and urgent maintenance. Reopening date to be communicated separately.